Survival analysis stratifying patients based on this criterion demonstrated that patients whose primary tumours had higher ZNF154 expression showed a significantly better overall survival when compared to the remaining cohort (Fig. 2A, Log-rank, p < 0.05). The gene discussed is ZNF154; the disease is neoplasm.